Kurome Therapeutics Inc

Kurome Therapeutics Inc. is a privately held company based in Cincinnati, Ohio. Currently employing 6 individuals, Kurome Therapeutics generates approximately $2.5 million in annual revenue. Kurome Therapeutics specializes in developing novel therapies targeting cancer cells that manipulate immune signaling pathways to evade traditional treatments. Their focus lies on creating IRAK1/4, panFLT3 inhibitors, demonstrated to effectively combat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in preclinical studies. Research conducted by Kurome Therapeutics highlights several promising advancements. Their inhibitors have shown synergistic effects when combined with Venclexta®, enhancing its potency. Notably, they've identified a biomarker correlating with AML patient prognosis and discovered methods to maximize immune signaling activation within AML cells. Preclinical trials using cell lines and patient-derived xenograft models have yielded impressive results, exceeding the efficacy of existing FLT3 inhibitors and demonstrating extended overall survival. Interested parties can explore Kurome Therapeutics' work further by visiting their website at kurometherapeutics.com.